SGLT2 in HF / Screening
Title & abstract screening
Inclusion criteria
✓HFrEF population (LVEF ≤ 40%)
✓SGLT2 inhibitor intervention
✓Randomised controlled trial
✓Reports HF hospitalisation or CV death
✕Animal / in-vitro studies
✕Non-English with no abstract
Throughput
6,610
screened · 71%
~9 min elapsed
Conflicts & low-confidence queue
Screener A Screener B Adjudicator| # | Study | A | B | Adjudicated |
|---|---|---|---|---|
| 2241 | Empagliflozin outcomes in chronic heart failure Zannad F, et al. · 2020 · RCT |
Incl | Incl | Include |
| 2242 | Dapagliflozin in patients with HFrEF McMurray JJV, et al. · 2019 |
Incl | Unsure | Review |
| 2243 | SGLT2i and renal endpoints in CKD cohort Heerspink HJL · 2020 · not HF pop |
Excl | Incl | Review |
| 2244 | Sotagliflozin in diabetes after worsening HF Bhatt DL · 2021 · RCT |
Incl | Incl | Include |
| 2245 | Mechanisms of SGLT2 inhibition (review) Narrative review · no outcomes |
Excl | Excl | Exclude |
| 2246 | Canagliflozin cardiovascular safety Neal B · 2017 · mixed pop |
Unsure | Excl | Review |
Selected · #2242
Dapagliflozin in patients with heart failure and reduced ejection fraction
In this trial, patients with NYHA class II–IV heart failure and an ejection fraction of 40% or less were randomised to dapagliflozin or placebo. The primary outcome was a composite of worsening heart failure or cardiovascular death…
Why Screener B said “unsure”
EF threshold matches, but abstract does not explicitly state randomisation method. Confidence 0.62 — below 0.75 gate → routed to adjudicator.
evidence span linked ↑ · model: screen-fast